{
    "nct_id": "NCT00381381",
    "title": "A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-12-10",
    "description_brief": "This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "recruitmentDetails": "This study was recruited at 15 centers in Korea during the period of June 2006 to August 2008.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Donepezil",
                    "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "199"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "135"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "64"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "52"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "9"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Donepezil",
                    "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "199"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.6",
                                            "spread": "6.5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "136"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "63"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "199"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)",
                    "description": "CERAD-K includes: Verbal Fluency-number of kinds of animal patients listed per minute, ranges from 0, no maximum point fixed.Boston Naming Test is naming objects (0-15). Mini-Mental State Examination in the Korean version of CERAD Assessment Packet (0-30). Word List Memory (0-30). Construction Praxis is from 0-11. Word List Recall and Word List Recognition ranges from 0-10.Construction Recall (0-11).",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on Scale",
                    "timeFrame": "26 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Donepezil",
                            "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "135"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Verbal Fluency",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.28",
                                            "spread": "3.71"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Boston Naming Test",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.31",
                                            "spread": "3.25"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "MMSE-KC",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.86",
                                            "spread": "5.25"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Word List Memory",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "10.62",
                                            "spread": "6.20"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Construction Praxis",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.61",
                                            "spread": "2.71"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Word List Recall",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.98",
                                            "spread": "1.99"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Word List Recognition",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.64",
                                            "spread": "3.24"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Construction Recall",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.11",
                                            "spread": "2.71"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatry Inventory (NPI)",
                    "description": "NPI score after treatment. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on Scale",
                    "timeFrame": "26 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Donepezil",
                            "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "135"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Delusions",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.49",
                                            "spread": "1.85"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Hallucinations",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.12",
                                            "spread": "0.69"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Agitation",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.54",
                                            "spread": "1.56"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Depression",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.76",
                                            "spread": "1.82"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Anxiety",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.70",
                                            "spread": "2.10"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Euphoria",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.02",
                                            "spread": "0.19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Apathy",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.44",
                                            "spread": "2.69"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Disinhibition",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.28",
                                            "spread": "1.19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Irritability",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.67",
                                            "spread": "1.93"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Aberrant motor behavior",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.44",
                                            "spread": "1.71"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Night-time behaviors",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.40",
                                            "spread": "1.68"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Appetite and eating disorders",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.43",
                                            "spread": "1.46"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "GDS-K (Geriatric Depression Scale-Korean) Score After Treatment",
                    "description": "GDS-K score after treatment. Geriatric Depression Scale is a basic screening measure for depression in older adults. It ranges from 0 to 30, and higher score represents more depressed.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Units on Scale",
                    "timeFrame": "26 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Donepezil",
                            "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "135"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "11.69",
                                            "spread": "6.42"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "CERAD-K",
                    "description": "CERAD-K includes: Trail making test A and B is scored by the time spent to link randomly arranged numbers and alphabets in correct order. Except Trail making test A and B, higher score presents better condition.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Second",
                    "timeFrame": "26 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Donepezil",
                            "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "135"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Trail making test A",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "206.64",
                                            "spread": "126.94"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Trail making test B",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "290.88",
                                            "spread": "30.20"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "1",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Donepezil",
                    "description": "Initial dose was 2.5 mg/day, and the maximum dose was 10 mg/day.",
                    "seriousNumAffected": 4,
                    "seriousNumAtRisk": 199,
                    "otherNumAffected": 30,
                    "otherNumAtRisk": 199
                }
            ],
            "seriousEvents": [
                {
                    "term": "Anorexia",
                    "organSystem": "Psychiatric disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "General Weakness",
                    "organSystem": "General disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Stroke",
                    "organSystem": "Vascular disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Ankle Fracture",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Malignancy Of Unknown Origin",
                    "organSystem": "General disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 199
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Weakness",
                    "organSystem": "General disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Anorexia",
                    "organSystem": "Psychiatric disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Abdominal Discomfort",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 199
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 199
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Jihee Mun, Pharmacist, Medical team manager",
                "organization": "Eisai Korea Inc.",
                "email": "jihee_mun@eisaikorea.com",
                "phone": "+82-2-3451-5531"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is donepezil, a centrally acting, reversible acetylcholinesterase (AChE) inhibitor that increases acetylcholine availability and is used to improve cognition and global function in patients with Alzheimer's disease (symptomatic treatment rather than disease modification). \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Act: Key extracted details \u2014 drug: donepezil (a small-molecule AChE inhibitor). The trial tests how Choline Acetyltransferase and Apolipoprotein E (APOE \u03b5) gene polymorphisms relate to the clinical response to donepezil in AD patients. Because donepezil's primary purpose is to improve cognitive symptoms (not to target core AD pathology like amyloid or tau), this fits the 'cognitive enhancer' category. \ue200cite\ue202turn0search7\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 donepezil is not considered a disease-modifying therapy (it alleviates cognitive symptoms but does not slow underlying neurodegeneration), so the trial's focus on genetic predictors of response to donepezil aligns with the cognitive-enhancer category rather than a disease-targeted biologic or small-molecule disease-modifier. No indication in the description that the trial is testing a disease-modifying mechanism or a neuropsychiatric-specific outcome, so 'cognitive enhancer' is the appropriate classification. \ue200cite\ue202turn0search7\ue202turn0search6\ue201",
        "Web search results used (brief): 1) Donepezil pharmacology and clinical profile (review noting reversible AChE inhibition and symptomatic use). \ue200cite\ue202turn0search0\ue201 2) Donepezil summary stating mechanism and that it improves cognition but is not proven to alter disease progression. \ue200cite\ue202turn0search7\ue201 3) Alzforum therapeutic summary describing donepezil's AChE inhibition and symptomatic benefit. \ue200cite\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests donepezil, a centrally acting, reversible acetylcholinesterase (AChE) inhibitor that increases acetylcholine availability and enhances cholinergic neurotransmission \u2014 a symptomatic, cholinergic (neurotransmitter) approach rather than amyloid/tau disease modification. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Extracted details \u2014 drug: donepezil (small\u2011molecule AChE inhibitor); trial evaluates how Choline Acetyltransferase (ChAT) and APOE \u03b5 polymorphisms relate to clinical response to donepezil (pharmacogenetic predictors of symptomatic response). These facts point to an intervention acting on neurotransmitter systems (cholinergic), so map to CADRO category D. \ue200cite\ue202turn0search4\ue202turn0search8\ue201",
        "Reflect: Classification check \u2014 donepezil's mechanism directly modulates cholinergic signaling at synapses (by preventing acetylcholine breakdown), which is best represented by CADRO 'Neurotransmitter Receptors' (D). The trial is not testing amyloid, tau, inflammation, or a disease\u2011modifying pathway; it is a symptomatic/cognitive\u2011enhancer pharmacogenetic study. No evidence of multi\u2011target or non\u2011therapeutic focus, so D) is the most specific fit. \ue200cite\ue202turn0search7\ue202turn0search6\ue201",
        "Web search results used (brief): 1) Donepezil mechanism and symptomatic use \u2014 PubMed / StatPearls reviews. \ue200cite\ue202turn0search1\ue202turn0search9\ue201 2) Pharmacology and clinical profile of donepezil (review). \ue200cite\ue202turn0search0\ue202turn0search5\ue201 3) Alzforum therapeutic summary (donepezil, cholinergic action). \ue200cite\ue202turn0search7\ue201 4) Pharmacogenetics / APOE and ChAT polymorphism studies and systematic review of APOE/CYP2D6 effects on donepezil response. \ue200cite\ue202turn0search4\ue202turn0search8\ue202turn0search2\ue201"
    ]
}